Oxaliplatin

Brand Name: Eloxatin

Manufacturer:

Indication

Indication:

For the treatment of colorectal cancer in both the adjuvant and metastatic settings. It is commonly used in combination with 5-fluorouracil and leucovorin (FOLFOX) or capecitabine (CAPOX/XELOX) for the treatment of stage III colon cancer after surgical resection and for metastatic colorectal cancer (mCRC) as first-line or subsequent therapy. Oxaliplatin is also included in the FOLFOXIRI regimen for selected patients with advanced disease.

Specific CRC Subtype: None

Stage: III, IV

Therapy Line: First-line, Third-line or later

Health Canada Approval: Approved

pCPA Negotiation Status:

Reimbursed in: AB (Alberta), BC (British Columbia), MB (Manitoba), NB (New Brunswick), NL (Newfoundland and Labrador), NS (Nova Scotia), NU (Nunavut), NWT (Northwest Territories), ON (Ontario), PEI (Prince Edward Island), QC (Quebec), SK (Saskatchewan), YU (Yukon)

New Search